|Bid||50.56 x 700|
|Ask||50.57 x 300|
|Day's Range||50.37 - 50.68|
|52 Week Range||30.89 - 50.95|
|PE Ratio (TTM)||20.85|
|Forward Dividend & Yield||0.95 (1.93%)|
|1y Target Est||50.20|
Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.
WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug. Shares in Novo Nordisk rose almost 3 percent in early trading on Thursday, after the panel late on Wednesday concluded semaglutide is effective, reasonably safe and should be approved by the FDA. The panel voted 16-0 with one abstention in favor of the drug being approved.
PLAINSBORO, N.J., Oct. 18, 2017 /PRNewswire/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) voted 16-0, supporting the approval of once-weekly semaglutide to improve glycemic control in adults with type 2 diabetes. Based on the data contained in the New Drug Application (NDA) for semaglutide, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to demonstrate the efficacy and safety profile of semaglutide for the treatment of type 2 diabetes in adults.
Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA typically follows the recommendations of its advisors. Novo Nordisk is hoping that semaglutide, administered through a once-weekly injection, will take market share from Eli Lilly & Co's once-weekly Trulicity, which in turn has been taking share from Novo Nordisk's once-daily Victoza.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.
Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, a preliminary review by the U.S. Food and Drug Administration concluded, sending the company's shares up 3.4 percent in premarket trading on Monday. The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of advisors to the agency who will discuss the drug, semaglutide, and recommend whether it should be approved. The FDA typically follows the recommendations of its advisors.
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.
The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.
New long-acting basal insulin now available to help adults living with type 1 and type 2 diabetes manage blood sugar levels MISSISSAUGA, ON , Oct. 3, 2017 /CNW/ - Today, Novo Nordisk announced the availability ...
Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.
Bagsværd, Denmark, 2 October 2017 - In continuation of the company`s announcements dated 3 May 2017 and 9 August 2017 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the ...
The U.S. Food and Drug Administration on Friday approved Novo Nordisk's fast-acting insulin to treat diabetes. The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. Fiasp, or faster acting insulin asparte, is designed to work faster than existing fast-acting insulin such as Eli Lilly and Co's Humalog and Novo Nordisk's own NovoLog, known as NovoRapid outside the United States.
PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp® (insulin aspart injection) 100 Units/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.1 Fiasp® can be dosed at the beginning of a meal or within 20 minutes after starting a meal. The result of this has led to many people with diabetes not achieving their target A1C.
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
PLAINSBORO, N.J., Sept. 26, 2017 /PRNewswire/ -- Novo Nordisk in the U.S. has been named to the "Working Mother 100 Best Companies" list which recognizes companies for their strong leadership in creating progressive workforce programs regarding advancement of women, flexibility, childcare and paid parental leave. The list is based on employee assessments. Earlier in this year, Novo Nordisk was recognized for the ninth consecutive year as a "Best Company to Work For" by Great Place to Work® and Fortune. "This year's winning companies know the value of keeping their employee moms engaged and supported," says Subha Barry, senior vice president & managing director of Working Mother Media.
In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.
In the first half of 2017, Novo Nordisk’s (NVO) Victoza generated revenues of DKK (Danish kroner) 11.5 billion, which reflected a ~21.0% rise on a YoY (year-over-year) basis.
In the first half of 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of DKK (Danish kroner) 284.0 million.
In the first half of 2017, Novo Nordisk’s (NVO) NovoRapid generated revenues of DKK (Danish kroner) 10.4 billion, which reflected a 9.0% rise on a YoY (year-over-year) basis.